The effect of propofol as an antioxidant agent in intravenous regional anesthesia
| dc.contributor.author | Erhan, O. L. | |
| dc.contributor.author | Bestas, A. | |
| dc.contributor.author | Gursu, F. | |
| dc.contributor.author | Alpay, N. | |
| dc.contributor.author | Ozer, A. B. | |
| dc.contributor.author | Gulcu, F. | |
| dc.date.accessioned | 2026-08-12T16:34:49Z | |
| dc.date.issued | 2006 | |
| dc.department | Fırat Üniversitesi | |
| dc.description.abstract | Intravenous regional anesthesia (IVRA) is a technique whereby a tourniquet is used to restrict blood flow to an exsanguinated limb. Propofol was shown to attenuate ischemia-reperfusion damage. We aimed to investigate the effect of low-dose propofol as an antioxidant in this process. Twenty-six unpremedicated adult patients (ASA I-II) were studied. The patients in the control group (Group C, n = 12) were administered 40 ml of 0.5% lidocaine, while the patients in the propofol group (Group P, n = 14) were administered 40 ml of 0.5% lidocaine plus 20 mg propofol for IVRA. Serum levels of malondialdehyde (MDA) and paraoxonase activity were measured at 1 min before, immediately upon, and 30 min after the release of the tourniquet. Serum paraoxonase activity was observed to have a significant decreasing course in both groups (p < 0.01). In contrast, we observed a progressive increase in the serum levels of MDA in Group C (p < 0.05). However, in Group P, serum levels of MDA after the release of the tourniquet periods were significantly lower than that before the release of the tourniquet (p < 0.05). The addition of propofol (20 mg) to lidocaine for IVRA inhibits MDA levels. We conclude that the addition of propofol to lidocaine can be considered as a useful antioxidant in this type of anesthesia. (c) 2006 Prous Science. All rights reserved. | |
| dc.identifier.doi | 10.1358/mf.2006.28.8.1003547 | |
| dc.identifier.endpage | 526 | |
| dc.identifier.issn | 0379-0355 | |
| dc.identifier.issue | 8 | |
| dc.identifier.orcid | 0000-0003-3552-7315 | |
| dc.identifier.pmid | 17136232 | |
| dc.identifier.scopus | 2-s2.0-33845361170 | |
| dc.identifier.scopusquality | N/A | |
| dc.identifier.startpage | 523 | |
| dc.identifier.uri | https://doi.org/10.1358/mf.2006.28.8.1003547 | |
| dc.identifier.uri | https://hdl.handle.net/11508/44632 | |
| dc.identifier.volume | 28 | |
| dc.identifier.wos | WOS:000242477800005 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Prous Science, Sa | |
| dc.relation.ispartof | Methods and Findings in Experimental and Clinical Pharmacology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | KA_WoS_20260511 | |
| dc.subject | intravenous regional anesthesia | |
| dc.subject | ischemia-reperfusion damage | |
| dc.subject | malondialdehyde | |
| dc.subject | paraoxonase | |
| dc.subject | propofol | |
| dc.title | The effect of propofol as an antioxidant agent in intravenous regional anesthesia | |
| dc.type | Article |







